On July 16th, Genetic Analysis AS (”Genetic Analysis” or the ”Company”) announced the publication of a peer-reviewed study in the scientific journal Gut Microbes, demonstrating that the GA-map® Dysbiosis Test delivers consistent results across geographically diverse populations. The findings address population variability, one of the challenges in microbiome diagnostics, and support the broader international applicability of the GA-map® platform.
Analyst Group’s View on the Publication
Analyst Group assesses the publication as a strategically important validation of the GA-map® platform, as it addresses what Analyst Group considers to be one of the largest challenges in the microbiome diagnostics market, the overall lack of standardization. As highlighted in our analysis, microbiome testing today is largely conducted using non-standardized, research-based platforms and in-house assays, which limits comparability and clinical reliability. By providing peer-reviewed evidence that the GA-map® approach reduces analytical variability while maintaining diagnostic performance across regions, the study strengthens the standardization narrative that underpins much of the Company’s investment case.
Stable Dysbiosis Index Across International Cohorts Supports Global Applicability
The study, ”Towards Standardized Gut Microbiota Diagnostics: Normobiosis Beyond Geographical Borders,” evaluated the GA-map® Dysbiosis Test across multiple international cohorts, analysing more than 800 samples from several countries. The Dysbiosis Index (DI), the core output of the test, remained stable across populations, with healthy individuals from different regions exhibiting comparable DI profiles and no systematic geographic bias in dysbiosis classification. Analyst Group assesses that demonstrating consistent classification against a common healthy reference population across regions is an important prerequisite for microbiome tests intended for widespread clinical use, and that it further differentiates the GA-map® platform from less standardized alternatives.
Independent Peer Review Reinforces the Platform’s Validation Base
Analyst Group assesses that the peer-reviewed nature of the publication is central to its significance, as independent scientific scrutiny carries greater weight with laboratories, healthcare providers, and potential partners than data communicated by the Company alone. The study adds to an already extensive evidence base, comprising nearly 60 peer-reviewed publications and more than 70 clinical studies, which Analyst Group has consistently viewed as a core competitive advantage, particularly as forthcoming IVDR requirements are expected to increase the emphasis on clinical validation and standardization.
Cross-Population Robustness Is Expected to Support Both Laboratory Adoption and Partnerships
From a financial perspective, Analyst Group assesses that the publication is expected to strengthen growth through two principal mechanisms. First, evidence of consistent performance across geographies lowers a barrier to international adoption, supporting installation of the GA-map® platform at new laboratories in new regions, which in turn is expected to drive recurring sales of high-margin reagent kits, the Company’s primary revenue source and the core of its scalable business model. Second, demonstrated cross-population robustness is assessed to strengthen the Company’s value proposition towards partners, including pharmaceutical companies and distributors, as standardized microbiome assessment that holds across populations is increasingly demanded in clinical trials and companion diagnostics settings, where the microbiome may affect treatment response.
Scientific Validation Strengthens the Long-Term Case Rather Than Near-Term Estimates
Adoption in the microbiome field remains characterized by long sales cycles and a gradual market shift, and the translation of scientific validation into installations and reagent kit volumes is expected to materialize over time rather than immediately. Analyst Group therefore views the publication primarily as a strengthening of the long-term investment case rather than a trigger for a near-term revision of estimates.
In summary, Analyst Group views the publication as a scientifically credible validation that reinforces the standardization narrative at the heart of the Company’s investment case. By evidencing consistent diagnostic performance across geographically diverse populations, the study supports the broader international applicability of the GA-map® platform and is expected to strengthen both laboratory adoption and partner-facing opportunities over time, though the impact is expected to accrue gradually rather than immediately.
